PCSK9 drugs for Atherosclerotic Cardiovascular Disease
19 tracked PCSK9 drugs in the Atherosclerotic Cardiovascular Disease race. The class explanation lives on the PCSK9 page; the full indication pipeline across every mechanism is on the Atherosclerotic Cardiovascular Disease page.
2 approved / phase 411 Phase 32 Phase 24 Phase 1
Head-to-head evidence: Alirocumab vs COR-1004 · Alirocumab vs DNV001 · Alirocumab vs Ebronucimab · Alirocumab vs Enlicitide · Alirocumab vs Evolocumab · Alirocumab vs HRS-1301